Research for clinical introduction of new cancer therapy targeting ubiquitin system
| Project/Area Number |
26861093
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
Migita Kazuhiro 奈良県立医科大学, 医学部附属病院, 研究員 (40570990)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | E3ユビキチンリガーゼ / 胃癌 / ユビキチン / RBX1 |
|---|
| Outline of Final Research Achievements |
We investigated the functions of Ring box protein-1 (RBX1) in tumors. In the immunohistochemical analyses, the patients with the RBX1-high tumor had a significantly lower overall survival rate than the patients with the RBX1-low tumor. Furthermore, RBX1 expression status was identified as an independent prognostic factor in the multivariate analysis. We further investigated the roles of RBX1 in vitro using the small interfering RNA (siRNA). RBX1 gene silencing significantly inhibited the proliferation of human gastric cancer cells through the cell cycle arrest. Furthermore, RBX1 gene silencing improved the sensitivity to the chemotherapeutic agent. In addition, migrated cells decreased significantly in the cells treated with RBX1 siRNA compared with the control. These findings indicate that RBX1 may be associated with the proliferation, metastasis, and resistance to chemotherapy in human cancers.
|
Report
(3 results)
Research Products
(1 results)
